Please login to the form below

Not currently logged in
Email:
Password:

HEOR

This page shows the latest HEOR news and features for those working in and with pharma, biotech and healthcare.

Latest news

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • The reality of real-world evidence The reality of real-world evidence

    The rise of health technology assessment (HTA) globally puts significant emphasis on health economic and outcome research (HEOR) analysis and RWE provides critical inputs into this.

  • Choosing wisely Choosing wisely

    If it's physicians or payers, it may be medical/HEOR. If you want to talk at the corporate level, market access and public affairs may play the lead role.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Along with the epidemiology and HEOR functions within the company, the new objective for the clinical team is to develop more efficient trial designs and a more realistic evidence basis for

  • The true meaning of market access? The true meaning of market access?

    Value creation through clinical and health economic outcomes and research (HEOR) data, and.

  • How to win through integrating market access How to win through integrating market access

    Only if this is addressed effectively in clinical development and HEOR, will the TPP be not just reimbursable but also funded from budgets at national, regional and local level.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics